Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the formula C17H24O3 and a molecular weight of approximately 276 g/mol[1][2][5]. It is listed as an experimental pharmaceutical in chemical databases and has been identified as a potential endocrine-disrupting compound[1]. Structural studies indicate it can bind to nuclear hormone receptors such as the estrogen receptor alpha ligand-binding domain (as seen in PDB structure complexes), suggesting it may act as a modulator of steroid hormone signaling pathways[6]. However its clinical development status and therapeutic indications are not established; it remains primarily an experimental or research tool.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[(1S,2S,5S,9R)-5-(hydroxymethyl)-8,9-dimethyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol.